Last reviewed · How we verify
Cycle 1 Induction
Cycle 1 Induction is a chemotherapy regimen used in hematologic malignancies to induce remission through cytotoxic drug combinations.
Cycle 1 Induction is a chemotherapy regimen used in hematologic malignancies to induce remission through cytotoxic drug combinations. Used for Acute leukemia induction therapy, Lymphoma induction therapy, Other hematologic malignancies requiring induction chemotherapy.
At a glance
| Generic name | Cycle 1 Induction |
|---|---|
| Also known as | VCR + IDR + DXM + ASP + IT |
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This is a treatment protocol rather than a single drug entity, typically consisting of multiple chemotherapeutic agents administered in a defined sequence during the initial induction phase of cancer treatment. The exact composition varies by protocol but generally aims to achieve maximal tumor cell kill and disease remission in hematologic malignancies.
Approved indications
- Acute leukemia induction therapy
- Lymphoma induction therapy
- Other hematologic malignancies requiring induction chemotherapy
Common side effects
- Myelosuppression
- Infection
- Nausea and vomiting
- Mucositis
- Alopecia
Key clinical trials
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (PHASE1)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |